JPWO2022006283A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022006283A5
JPWO2022006283A5 JP2022581408A JP2022581408A JPWO2022006283A5 JP WO2022006283 A5 JPWO2022006283 A5 JP WO2022006283A5 JP 2022581408 A JP2022581408 A JP 2022581408A JP 2022581408 A JP2022581408 A JP 2022581408A JP WO2022006283 A5 JPWO2022006283 A5 JP WO2022006283A5
Authority
JP
Japan
Prior art keywords
subject
administration
pharmaceutical composition
nmosd
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022581408A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023534916A (ja
JP2023534916A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/039911 external-priority patent/WO2022006283A2/en
Publication of JP2023534916A publication Critical patent/JP2023534916A/ja
Publication of JP2023534916A5 publication Critical patent/JP2023534916A5/ja
Publication of JPWO2022006283A5 publication Critical patent/JPWO2022006283A5/ja
Pending legal-status Critical Current

Links

JP2022581408A 2020-06-30 2021-06-30 視神経脊髄炎スペクトラム障害を治療する方法 Pending JP2023534916A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063046133P 2020-06-30 2020-06-30
US63/046,133 2020-06-30
US202063052093P 2020-07-15 2020-07-15
US63/052,093 2020-07-15
US202063071092P 2020-08-27 2020-08-27
US63/071,092 2020-08-27
PCT/US2021/039911 WO2022006283A2 (en) 2020-06-30 2021-06-30 Methods of treating neuromyelitis optica spectrum disorder

Publications (3)

Publication Number Publication Date
JP2023534916A JP2023534916A (ja) 2023-08-15
JP2023534916A5 JP2023534916A5 (https=) 2024-07-09
JPWO2022006283A5 true JPWO2022006283A5 (https=) 2024-07-09

Family

ID=79321915

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022581408A Pending JP2023534916A (ja) 2020-06-30 2021-06-30 視神経脊髄炎スペクトラム障害を治療する方法

Country Status (11)

Country Link
US (1) US20230406928A1 (https=)
EP (1) EP4172211A4 (https=)
JP (1) JP2023534916A (https=)
KR (1) KR20230030642A (https=)
CN (1) CN116234571A (https=)
AU (1) AU2021299307A1 (https=)
BR (1) BR112022026747A2 (https=)
CA (1) CA3178954A1 (https=)
IL (1) IL299381A (https=)
MX (1) MX2022016236A (https=)
WO (1) WO2022006283A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023549075A (ja) * 2020-10-29 2023-11-22 ビエラ バイオ インコーポレイテッド 自己免疫疾患を治療するための抗cd19抗体の使用
CN117797245A (zh) * 2023-12-29 2024-04-02 广州赛莱拉干细胞科技股份有限公司 人乳脂球表皮生长因子8用于制备治疗视神经脊髓炎谱系疾病药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021012870A (es) * 2019-04-24 2022-01-18 Viela Bio Inc Uso de un anticuerpo anti cúmulo de diferenciación 19 (cd19) para tratar enfermedades autoinmunitarias.
JP2023549075A (ja) * 2020-10-29 2023-11-22 ビエラ バイオ インコーポレイテッド 自己免疫疾患を治療するための抗cd19抗体の使用

Similar Documents

Publication Publication Date Title
Bachurin et al. Mild cognitive impairment due to Alzheimer disease: Contemporary approaches to diagnostics and pharmacological intervention
Nasr et al. ADEM: literature review and case report of acute psychosis presentation
JP2024112859A5 (https=)
JP2023116770A5 (https=)
JP7541505B2 (ja) アルツハイマー病の治療及び予防方法
JP2021532126A5 (https=)
JP2015527364A (ja) Il−4rアンタゴニストを投与することにより喘息を処置又は予防するための方法
CN114173819A (zh) 通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法
JP2022033868A5 (https=)
RU2006120950A (ru) Антитело к cd40: препарат и способы
EP3487881A1 (en) Methods of treating new-onset plaque type psoriasis using il-17 antagonists
CN114401742B (zh) 通过转换疗法治疗rms
JP2019519584A (ja) アミロイドーシスを処置するための組成物
CN114375306A (zh) 奥法木单抗治疗患者中除多发性硬化症以外病症的管理
TW202430554A (zh) 使用tau PET水平之治療方法
JP2021529766A5 (https=)
JP7781519B2 (ja) グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法
JP2022125248A (ja) 視神経脊髄炎スペクトル障害の治療に有用な組成物及び方法
JPWO2022006283A5 (https=)
Comi Early treatment
US20230025707A1 (en) Anti-Alpha-Synuclein Monoclonal Antibodies, and Methods Using Same
TW202120546A (zh) 使用介白素-17(il-17)拮抗劑治療狼瘡性腎炎之方法
JP2024535831A (ja) 結節性痒疹の治療のためのil-13阻害剤
JPWO2020010024A5 (https=)
Golden A Review of Multiple Sclerosis Treatments: Interferon Beta, Glatiramer Acetate, Fingolimod, and Natalizumab